Business Description
RemeGen Co Ltd
ISIN : CNE1000048G6
Share Class Description:
HKSE:09995: Class HCompare
Compare
Traded in other countries / regions
09995.Hong Kong688331.ChinaREG.GermanyREGMF.USA IPO Date
2020-11-09Description
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.58 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | -2.01 | |||||
| Altman Z-Score | 9.21 | |||||
| Beneish M-Score | 31.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.4 | |||||
| 3-Year EPS without NRI Growth Rate | -28.1 | |||||
| 3-Year FCF Growth Rate | -73.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.32 | |||||
| 9-Day RSI | 60.82 | |||||
| 14-Day RSI | 58.98 | |||||
| 6-1 Month Momentum % | -30.85 | |||||
| 12-1 Month Momentum % | -44.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.96 | |||||
| Quick Ratio | 1.31 | |||||
| Cash Ratio | 0.64 | |||||
| Days Inventory | 1994.01 | |||||
| Days Sales Outstanding | 146.4 | |||||
| Days Payable | 630.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -1.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.83 | |||||
| Operating Margin % | -111.17 | |||||
| Net Margin % | -116.87 | |||||
| ROE % | -14.93 | |||||
| ROA % | -10.93 | |||||
| ROIC % | -16.59 | |||||
| ROC (Joel Greenblatt) % | -19.35 | |||||
| ROCE % | -12.9 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 27.27 | |||||
| PB Ratio | 4.36 | |||||
| Price-to-Tangible-Book | 4.41 | |||||
| EV-to-EBIT | -40.11 | |||||
| EV-to-Forward-EBIT | -18.67 | |||||
| EV-to-EBITDA | -40.11 | |||||
| EV-to-Forward-EBITDA | -24.42 | |||||
| EV-to-Revenue | 46.08 | |||||
| EV-to-Forward-Revenue | 16.16 | |||||
| EV-to-FCF | -12.19 | |||||
| Price-to-Net-Current-Asset-Value | 108.93 | |||||
| Earnings Yield (Greenblatt) % | -2.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RemeGen Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 597.138 | ||
| EPS (TTM) (HK$) | -2.701 | ||
| Beta | 0.78 | ||
| Volatility % | 97.06 | ||
| 14-Day RSI | 58.98 | ||
| 14-Day ATR (HK$) | 2.036318 | ||
| 20-Day SMA (HK$) | 29.085 | ||
| 12-1 Month Momentum % | -44.39 | ||
| 52-Week Range (HK$) | 14.96 - 50.3 | ||
| Shares Outstanding (Mil) | 544.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RemeGen Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RemeGen Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
RemeGen Co Ltd Frequently Asked Questions
What is RemeGen Co Ltd(HKSE:09995)'s stock price today?
The current price of HKSE:09995 is HK$30.50. The 52 week high of HKSE:09995 is HK$50.30 and 52 week low is HK$14.96.
When is next earnings date of RemeGen Co Ltd(HKSE:09995)?
The next earnings date of RemeGen Co Ltd(HKSE:09995) is 2024-05-31 Est..
Does RemeGen Co Ltd(HKSE:09995) pay dividends? If so, how much?
RemeGen Co Ltd(HKSE:09995) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers